PHARMACOLOGICAL MODULATION OF EPIGENETIC CHANTGES IN AML
AML 表观遗传变化的药理学调节
基本信息
- 批准号:6872881
- 负责人:
- 金额:$ 30.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-04-01 至 2007-03-31
- 项目状态:已结题
- 来源:
- 关键词:DNA methylationacetylationacute myelogenous leukemiaamidohydrolasesantineoplasticsapoptosiscarcinogenesischromatinclinical researchclinical trial phase Idosageenzyme inhibitorsgene expressiongene induction /repressionhistoneshuman subjecthuman therapy evaluationmethyltransferaseneoplasm /cancer chemotherapyneoplasm /cancer geneticsneoplasm /cancer pharmacologypatient oriented researchpharmacokineticsposttranslational modificationsvalproate
项目摘要
DESCRIPTION (provided by applicant): The role that epigenetic changes (i.e., histone deacetylation and DNA methylation) play in the aberrant silencing of tumor suppressor genes in malignant cells has been well established. There is now general consensus that both aberrant histone deacetylation and DNA methylation contribute to leukemogenesis in AML. Recent studies focused on the molecular basis of epigenetic transcriptional silencing support the concept that nuclear histones interact with DNA methylation in a dynamic way to repress genes important for hematopoietic differentiation and apoptosis. Genomic silencing induced by these mechanisms can be relieved by pharmacological modulation with histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors. Preclinical work in AML has demonstrated in vitro synergy of these agents that raises the hope of clinical synergy. However, little is known about the specificity of this strategy for inhibiting specific HDAC and DNMT enzyme subtypes or the kinetics of enzyme inhibition and how this relates to clinic benefit in AML patients. Therefore, to understand their full potential, a systematic study of the pharmacological and biological effects induced by HDAC and DNMT inhibitors in the context of clinical trials is required. Here we propose to explore combination of agents with a demonstrated inhibitory activity to the histone deacetylation and DNA methylation machinery in AML. We hypothesize that the therapeutic application of these agents will restore normal patterns of gene expression, activate terminal differentiation and lower the apoptotic threshold in the leukemic cells, and thereby induce clinical benefit. To test these hypotheses, our specific aims are 1) to perform a phase I study in AML using agents that affect the DNA methylation machinery (i.e., decitabine) and chromatin structure (i.e., valproic acid); 2) to perform pharmacokinetic and pharmacodynamic studies of these agents that will allow correlations of drug plasma levels, chromatin changes and gene re-expression with toxicity and disease response.
描述(由申请人提供):表观遗传变化(即组蛋白去乙酰化和DNA甲基化)在恶性细胞中肿瘤抑制基因异常沉默中的作用已经得到了很好的证实。目前普遍认为,异常组蛋白去乙酰化和DNA甲基化都有助于AML的白血病发生。最近对表观遗传转录沉默分子基础的研究支持核组蛋白以动态方式与DNA甲基化相互作用以抑制造血分化和细胞凋亡重要基因的概念。这些机制诱导的基因组沉默可以通过组蛋白去乙酰化酶(HDAC)和DNA甲基转移酶(DNMT)抑制剂进行药理学调节来缓解。AML的临床前工作已经证明了这些药物的体外协同作用,这增加了临床协同作用的希望。然而,对于这种策略抑制特定HDAC和DNMT酶亚型的特异性或酶抑制动力学以及这与AML患者临床获益的关系知之甚少。因此,为了充分了解它们的潜力,需要在临床试验的背景下对HDAC和DNMT抑制剂诱导的药理学和生物学效应进行系统研究。在这里,我们建议探索对AML中组蛋白去乙酰化和DNA甲基化机制具有抑制活性的药物组合。我们假设这些药物的治疗应用将恢复正常的基因表达模式,激活白血病细胞的终末分化和降低凋亡阈值,从而诱导临床获益。为了验证这些假设,我们的具体目标是:1)在AML中使用影响DNA甲基化机制(即地西他滨)和染色质结构(即丙戊酸)的药物进行I期研究;2)对这些药物进行药代动力学和药效学研究,以确定药物血浆水平、染色质变化和基因再表达与毒性和疾病反应之间的相关性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GUIDO MARCUCCI其他文献
GUIDO MARCUCCI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GUIDO MARCUCCI', 18)}}的其他基金
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML
miR-142 在克隆性造血障碍转化为 AML 中的作用
- 批准号:
10367856 - 财政年份:2022
- 资助金额:
$ 30.37万 - 项目类别:
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML
miR-142 在克隆性造血障碍转化为 AML 中的作用
- 批准号:
10544734 - 财政年份:2022
- 资助金额:
$ 30.37万 - 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
- 批准号:
10371023 - 财政年份:2020
- 资助金额:
$ 30.37万 - 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
- 批准号:
10094210 - 财政年份:2020
- 资助金额:
$ 30.37万 - 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
- 批准号:
10600088 - 财政年份:2020
- 资助金额:
$ 30.37万 - 项目类别:
Validation of microRNAs as therapeutic targets in hematological malignancies
验证 microRNA 作为血液恶性肿瘤治疗靶点
- 批准号:
8815267 - 财政年份:2011
- 资助金额:
$ 30.37万 - 项目类别:
Validation of microRNAs as therapeutic targets in hematological malignancies
验证 microRNA 作为血液恶性肿瘤治疗靶点
- 批准号:
8627134 - 财政年份:2011
- 资助金额:
$ 30.37万 - 项目类别:
Molecular characterization of normal cytogenetics AML in older patients
老年患者正常细胞遗传学 AML 的分子特征
- 批准号:
7471096 - 财政年份:2008
- 资助金额:
$ 30.37万 - 项目类别:
Molecular characterization of normal cytogenetics AML in older patients
老年患者正常细胞遗传学 AML 的分子特征
- 批准号:
7614313 - 财政年份:2008
- 资助金额:
$ 30.37万 - 项目类别:
相似国自然基金
海马神经元胆固醇代谢重编程致染色质组蛋白乙酰化水平降低介导老年小鼠术后认知功能障碍
- 批准号:82371192
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
HK2乳酰化修饰介导巨噬细胞功能障碍在脓毒症中的作用及机制
- 批准号:82372160
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
组蛋白乙酰化修饰ATG13激活自噬在牵张应力介导骨缝Gli1+干细胞成骨中的机制研究
- 批准号:82370988
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
相似海外基金
Cancer-based discovery of novel mechanisms of chromatin control
基于癌症的染色质控制新机制的发现
- 批准号:
10660680 - 财政年份:2023
- 资助金额:
$ 30.37万 - 项目类别:
Knowledgebase of Escherichia coli Genome and Metabolism
大肠杆菌基因组和代谢知识库
- 批准号:
10716050 - 财政年份:2023
- 资助金额:
$ 30.37万 - 项目类别:
Using Common Fund Datasets to Illuminate Drug-Microbial Interactions
使用共同基金数据集阐明药物-微生物相互作用
- 批准号:
10777339 - 财政年份:2023
- 资助金额:
$ 30.37万 - 项目类别:
Mechanism of Transcriptional Regulation of Th2 Cell Development
Th2细胞发育的转录调控机制
- 批准号:
10716014 - 财政年份:2023
- 资助金额:
$ 30.37万 - 项目类别:
Pilot Studies of PAX3-FOXO1 Fusions Proteins in Alveolar Rhabdomyosarcoma
PAX3-FOXO1 融合蛋白在肺泡横纹肌肉瘤中的初步研究
- 批准号:
10726763 - 财政年份:2023
- 资助金额:
$ 30.37万 - 项目类别:
Dissecting out differential molecular phenotypes across Lysine(K) AcetylTransferase mutations in mouse development
剖析小鼠发育过程中赖氨酸(K)乙酰转移酶突变的差异分子表型
- 批准号:
10727966 - 财政年份:2023
- 资助金额:
$ 30.37万 - 项目类别:
Targeting HNF4-induced thrombo-inflammation in Chagas disease
针对恰加斯病中 HNF4 诱导的血栓炎症
- 批准号:
10727268 - 财政年份:2023
- 资助金额:
$ 30.37万 - 项目类别:
Metabolic mechanisms underlying bronchopulmonary dysplasia-associated pulmonary hypertension
支气管肺发育不良相关肺动脉高压的代谢机制
- 批准号:
10736803 - 财政年份:2023
- 资助金额:
$ 30.37万 - 项目类别: